Back to School: How biopharma can reboot drug development. Access exclusive analysis here
BBG will merge with VER in a stock deal in which BBG shareholders will own 47% of the new company and VER shareholders will own 53%. BBG
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury